These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 22390279

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.
    Triscott J, Lee C, Foster C, Manoranjan B, Pambid MR, Berns R, Fotovati A, Venugopal C, O'Halloran K, Narendran A, Hawkins C, Ramaswamy V, Bouffet E, Taylor MD, Singhal A, Hukin J, Rassekh R, Yip S, Northcott P, Singh SK, Dunham C, Dunn SE.
    Cancer Res; 2013 Nov 15; 73(22):6734-44. PubMed ID: 24019381
    [Abstract] [Full Text] [Related]

  • 4. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
    Hu K, Law JH, Fotovati A, Dunn SE.
    Breast Cancer Res; 2012 Feb 06; 14(1):R22. PubMed ID: 22309939
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
    Gerster K, Shi W, Ng B, Yue S, Ito E, Waldron J, Gilbert R, Liu FF.
    Int J Radiat Oncol Biol Phys; 2010 May 01; 77(1):253-60. PubMed ID: 20394857
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X, Choy E, Harmon D, Yang S, Yang C, Mankin H, Hornicek FJ, Duan Z.
    Anticancer Drugs; 2011 Jun 01; 22(5):444-53. PubMed ID: 21399492
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
    Cholewa BD, Ndiaye MA, Huang W, Liu X, Ahmad N.
    Cancer Lett; 2017 Jan 28; 385():179-187. PubMed ID: 27793694
    [Abstract] [Full Text] [Related]

  • 12. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
    Ding Y, Huang D, Zhang Z, Smith J, Petillo D, Looyenga BD, Feenstra K, Mackeigan JP, Furge KA, Teh BT.
    Cancer Res; 2011 Aug 01; 71(15):5225-34. PubMed ID: 21642374
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
    Valianou M, Cox AM, Pichette B, Hartley S, Paladhi UR, Astrinidis A.
    Cell Cycle; 2015 Aug 01; 14(3):399-407. PubMed ID: 25565629
    [Abstract] [Full Text] [Related]

  • 15. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.
    Lansing TJ, McConnell RT, Duckett DR, Spehar GM, Knick VB, Hassler DF, Noro N, Furuta M, Emmitte KA, Gilmer TM, Mook RA, Cheung M.
    Mol Cancer Ther; 2007 Feb 01; 6(2):450-9. PubMed ID: 17267659
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of polo-like kinase 1 promotes hyperthermia sensitivity via inactivation of heat shock transcription factor 1 in human retinoblastoma cells.
    Yunoki T, Tabuchi Y, Hayashi A, Kondo T.
    Invest Ophthalmol Vis Sci; 2013 Dec 23; 54(13):8353-63. PubMed ID: 24366665
    [Abstract] [Full Text] [Related]

  • 17. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
    Nihal M, Stutz N, Schmit T, Ahmad N, Wood GS.
    Cell Cycle; 2011 Apr 15; 10(8):1303-11. PubMed ID: 21436619
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Mitotic arrest and slippage induced by pharmacological inhibition of Polo-like kinase 1.
    Raab M, Krämer A, Hehlgans S, Sanhaji M, Kurunci-Csacsko E, Dötsch C, Bug G, Ottmann O, Becker S, Pachl F, Kuster B, Strebhardt K.
    Mol Oncol; 2015 Jan 15; 9(1):140-54. PubMed ID: 25169932
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.